Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1772)	12/31/2001 4:12:55 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 2515

Let me admit that I don't own one share..so I don't have an axe to grind, but the following it what investors should be concerned with.... "Furthermore, ImClone said the FDA believed the documentation in the approval application was not sufficient to prove that patient tumors actually shrank after being treated with Erbitux." I don't care what spin the CEO puts out, with the climate and review process that the FDA has gone through in the past few months....there is no DAMN excuse that IMCL shouldn't have known what was expected of them in this filing. All the spin in the world and with BMY looking over their shoulder, there is no way to explain that they didn't merely overlook this data....IMO it ain't there. The very fact that they HAVE BEEN working closely with the FDA in the manner in which they filed this document and NO ONE mentioned until last Friday afternoon after the closing of the market..."OH! By the way. Your filing isn't complete IMCL CEO."